drugset
drugset / Trial / NCT03605849

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

NCT03605849 ↗

Phase 3 Completed 662 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study evaluated the long-term safety and tolerability of centanafadine sustained-release (SR) tablets, administered twice daily (BID) in the treatment of adults with attention deficit hyperactivity disorder (ADHD).

Timeline

Start
2019-02-14
Primary completion
2021-09-07
Completion
2021-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Centanafadine Small molecule 200 mg Oral

Indications

attention deficit-hyperactivity disorder